Synthetic Genomics Options for Governance


Michele S. Garfinkel

J. Craig Venter Institute



Synthetic genomics at JCVI


ΦX174 synthesis








External Events Influence How a Technology is Perceived



External Events Influence How a Technology is Perceived



INSTITUTE

Governance Concerns Related to Synthetic Genomics

- Along with the promise of benefits, all new technologies raise societal concerns
- Five key societal concerns:
 - Bioterrorism
 - Laboratory Safety
 - Harm to the Environment
 - Distribution of Benefits
 - Ethical and Religious Concerns



Bioterrorism

- Societal concerns
 - New way to obtain pathogens
 - Construction of a pathogen with increased resistance to known treatments or increased virulence
- What is different about synthetic genomics?
 - Can no longer limit access by physical means alone
 - Most pathogens easier to obtain by other means
 - Except a few viruses: 1918 influenza, Smallpox, Ebola

J. Craig Venter

Laboratory Safety


- Societal concerns
 - Concern is for risks to users from specific microbes
 - No concern for harm to users from synthetic DNA itself
- What is different about synthetic genomics?
 - Speed and scale
 - Researchers new to the field




ance	Michele S. Garfinkel, The J. Coag Venter Institute, Rockville, Maryland, Drew Endy, Massachusetts Institute of Technology, Cambridge, Massachusetts, Gerald L. Epstein, Center for Strategic and International Studies, Washington, District of Columbia and Robert M. Friedman, The J. Craig Venter Institute, Rockville, Maryland October 2007
Options for Governance	Technology, mbia and F
for G	strict of Colo
tions	dasachusen shington, Dis aig Vente
<i>dO</i>	ww Endy, A Studies, Wo J. Cr
S C	ryland, Dre
υ Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε Ε	Sociale, Mc Socialite, Mc Ingra and It
Z ш	er Institute, I ockville, Ma
). Craig Vent pstein, Ca r Institute. R
S ≺ N H E H T C	inkel, The
± ⊢ Z	Michele S. Garl Mossochusetts, G. Friedman, The J. October 2007
≻ ∽	Miche Massa Fried

				ဗီ	Gene Firms	SI		Oligo Ma	Oligo Manufacturers			A Synt	DNA Synthesizers		Ŋ	Users and	Organi	Organizations
Does the Option: Enhance Biosecurity	M. J. Ge.	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	A Solo Solo Solo Solo Solo Solo Solo Sol	40792 42470 43970	400 50 45 100 100 100 100 100 100 100 100 100 10	146	A Stock of the state of the sta	To the post of the sold of the	Ario and the state of the state	Sulla Managaria de la constanta	Popular States of the States o	2 of Dr. Sales of Up of Or Dr. A. O. O. O. D. Dr. O. Dr. O	Signal of the services of the		430 501 18 18 18 18 18 18 18 18 18 18 18 18 18	Jel nelbillen og	20, 19/10/18/2002 19/19/2002 19/1	24 192 186 187 187 187 187 187 187 187 187 187 187
by preventing incidents?	0	0	•	0	0		0	0	0		0	0	ı		0		0	
by helping to respond?		I		0	I	I		0	0	0	0	0	1	ı		1		
Foster Laboratory Safety									-									
by preventing incidents?	0		0		0	I	0	I	ı	I	ı	0	•	0	0	0	0	
by helping to respond?	I	I	I			I	I	ı	I	I	ı	0	ı	ı	I	0	ı	
Protect the Environment																		
by preventing incidents?	0		0					l			I	0	•	0	0	0	0	
by helping to respond?	I	I	I	0	I	I	ı	0	ı	I	I	0	0	0	0	I	I	
Other Considerations:	::																	
Minimize costs and burdens to government and industry?	0	0	0	•	0	0	0	•	•	0	0	0	0	0	0	0	0	
Perform to potential without additional research?	0	•	0	0	0	•	0	0	•	•	0	0	0	0	0	0	0	
Not impede research?	0	0	0	•	0	0	0	•	0	0	0	•	0	•	0	0	0	
Promote constructive applications?	I	I	ı	ı	I	I	I	ı	ı	I	ı	•	0	0	0	ı	I	

A synthetic chromosome








Synthetic genomics at JCVI


Enzymatic assembly of multi-kilobase molecules






Synthetic genomics at JCVI

One-step assembly of *M. genitalium* genome






Schematic overview and timeline for the assembly of overlapping ssDNA oligonucleotides (orange lines with blue circles) into a linear dsDNA yeast/E. coli shuttle vector (pRS313; grey) within the nucleus of a yeast cell



Gibson, D. G. Nucl. Acids Res. 2009 37:6984-6990; doi:10.1093/nar/gkp687

Twenty base-pair overlaps are sufficient for oligonucleotide assembly in yeast



Gibson, D. G. Nucl. Acids Res. 2009 37:6984-6990; doi:10.1093/nar/gkp687

Societal Concerns Related to Synthetic Genomics

- Five key societal concerns:
 - Bioterrorism
 - Laboratory Safety
 - Harm to the Environment
 - Distribution of Benefits
 - Ethical and Religious Concerns



Harm to the Environment

- Societal concerns
 - No concern for harm from synthetic DNA itself
 - Only concern is whether specific engineered organisms pose risks to the environment
 - Part of larger societal debate about rDNA since the mid-1970s (starting with Asilomar)
- What is different about synthetic genomics?
 - Speed, scale, power of the technology



Distribution of Benefits

- Societal concerns
 - Intellectual property concerns
 - Patents, open source
 - "Concentration" within a small number of firms
- What is different about synthetic genomics?
 - Maybe little; raised for every emerging technology
 - However, the synthetic biology community itself is divided on this issue



Ethical and Religious Concerns

- Societal concerns
 - Hubris ("playing God")
 - Concerns about changing the relationship of humans to nature
- What is different about synthetic genomics?
 - Construction of a free-living organism from chemicals adds a new concern to the list



Stakeholders

- Citizens
- Consumers
- Businesses
- Scientists

- Policymakers
- Governments
- Do-it-yourself community

And their representative groups



Regulation and governance of synthetic genomics

- Changes to NIH guidelines?
- Changes to Coordinated Framework?
- Changes to TSCA?
- Changes in patent review (domestic and international)?



Where we are today...

- The technology is improving and the user base is expanding
- Applications are beginning to appear and many new ones are being developed
- Societal impacts are being scrutinized
- Governance options are being seriously considered...
 - By the research community itself, the developing industry, and by governments



Disclaimer

This paper was produced for a meeting organized Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.

